Andrew has spent a large proportion of his career as an officer in the military, a Dartmouth trained Royal Naval Officer with a strong interest in science Andrew served on a significant number of RN ships, conducting Land and Maritime Operations, gaining considerable experience and skills in logistical and project management, as well as the direct management of those under his command. On retiring from the Royal Navy it was always Andrew’s intention to move into business and he has been involved in a number of entrepreneurial projects.
Michelle has been a Surgeon Practitioner for over 17 years; Specialising in cardiac and orthopedic surgery, with responsibilities for management of junior doctors’ in house training and surgical skills, along with day to day NHS departmental management. Michelle has also ran her own dental cosmetics business for 4 years. Her extensive medical and life science experience will be invaluable, particularly with respect to cardiovascular and coronary artery disease when focusing on the imaging requirements, and as link / co-ordinator of all aspects of the future business.
Mark is Professor of Nanotechnology at Kings College London responsible for a 15 person research group exploring the interface between nanomaterials and biology; a post-doctoral fellow at Imperial College & University of Oxford, Mark also worked as a Scientist at Oxonica Ltd for 4 years before joining King’s as a lecturer in bio-nanotechnology in 2004, progressing to Senior Lecturer, Reader, before becoming a Professor in 2014. Mark has been involved in spin offs from Oxford, namely Oxonica and Opsys.
Research interests include, organometallic-based synthesis of semiconductor and metal nanoparticles, biological applications of nanomaterials, rare-earth based nanomaterials, biosynthesis, conjugated polymer nanoparticles. 15 years of research to date has yielded the current patents relating to CPN’s, on which he is the named inventor.
Peter has over 25 years in the commercial area of life sciences, and marketing. He is Marketing Director of THL Worldwide Ltd, and a Trustee of the Coronary Thrombosis Trust, (established to fund research into coronary thrombosis and the prevention of coronary heart disease). Working alongside Prof. Mark Noble, Hon. Professor of Cardiovascular Medicine at Aberdeen University; THL has recently started phase II trials for Thromboserin, a potent inhibitor of coronary thrombosis.
Peter is also CEO of Notch Communications Ltd, a brand marketing and advertising agency focusing on Life Science and Pharmaceuticals. Current clients include Sigma-Aldrich, Cancer Research UK, Xerox Research and Johnson Matthey. Peter began his marketing career working for J.Walter Thompson and McCann Erickson before moving into life science marketing and working with companies including ICI, Zeneca, Monsanto and the American Chemical Society.
Steve brings a wealth of experience to Stream, joining from e-Therapeutics Ltd. His career began in The Wellcome Foundation, in R&D and Operations. He rose to become the Head of Project Management for the Wellcome Group, involved in all aspects of NCE and NBE development, driving the overall strategy, portfolio review and with full responsibility for budgets/financial control. When Glaxo acquired Wellcome, Steve helped integrate the two R&D organisations. On completion, Steve joined the Boots Healthcare International team as Head of Development for OTC products in the respiratory/analgesic range of products, before moving to Merck Generics to become the Head of World Wide R&D, responsible for over 11 major sites and 1000 R&D staff. In 2007 Steve was part of the management team that successfully sold the Group to Mylan for over $7 billion. He has also worked for several Private Equity Groups including helping Apax partners prepare the US company Qualitest for its eventual sale to Endo.
Dermott is an accomplished molecular biologist with over 16 years experience in the pharmaceutical industry working for AstraZeneca, Pfizer and as an independent consultant. During this time he gained extensive scientific and technical expertise in all stages of product development, project management and drug discovery, from target identification to candidate drug selection. Over the last 7 years he has lead his own drug discovery consultancy practice enabling clients to bring new technologies to market, integrate novel techniques to enhance their capabilities, and has successfully managed numerous drug discovery projects both within large pharmaceutical companies and as part of drug discovery consortia. His focus has been on the application of novel technologies to drug discovery, with an emphasis on fluorescent and electrophysiological approaches. Dermott’s in-depth knowledge of numerous drug discovery techniques, in-vitro processes, and applications of the latest industry technology within the field of molecular biology is now being applied to product definition of Stream’s core technology.
David has over 25 years experience in pharmaceutical industry R&D and is Chief Development Officer at Haoma Medica, formally head of R&D for Evgen Pharma. Prior, David has been a Freelance Preclinical Development and Project Management Consultant. In this role he was responsible for the establishment and development of infrastructure, project plans, the establishing of contracts for manufacturing, analysis, safety, assessment and Phase I & II regulatory filings for a number of small drug & mid sized pharmaceutical development companies.
Prior to 2003, David was Head of Project Management for KS Biomedix Holdings, a biopharmaceutical company developing a pipeline of drugs for a range of cancer indications. He was formerly the Director of Preclinical Development for NicOx SA and was a Team Leader at Celltech Chiroscience.
Stuart served in the Royal Navy as an Officer and Helicopter pilot, ending his career as a Search and Rescue mission Commander, a role he continued as a Reservist until the Military handed over responsibility to the Coast Guard in 2016. During his RN service Stuart was responsible for unit level CBRN training and response, and developed a high level of management and project skills. Stuart holds a Distinction from City University in Air Transport and Safety Management, and a MCGI in Leadership and Management and runs his own training consultancy, Gradient Force. He is also a Co-Director of PSA, a company delivering training in Human Factors, TRiM, CISM and Stress Resilience, clients include; Emergency Medical Retrieval Service, West Yorkshire Police Federation, Mountain Rescue Council of Scotland, NHS Ayrshire and Arran.
In 2016 he was seconded to the DfT for the appraisal and award of the UK SAR H contract, a £3 billion project running for 10 years. Since retiring from the RN Reserve, Stuart continues his interest in CBRNe and developing new systems to protect personnel operating in hostile environments and is focussed on developing Stream’s technology in this area.
Andrew graduated with a degree in Politics, History and Philosophy from Huddersfield University and then studied law at Manchester, before qualifying as a solicitor in 1994. Specialising in Corporate and Commercial work for nearly 25 years, Andrew brings a vast spread of corporate experience to Stream, having dealt with small SME businesses through to large multi-national corporations across a wide range of industry sectors. Recent transactions Andrew has been responsible for, includes the disposal of a multi-national group of pharmaceutical distribution companies, and the second-round fundraising for the Outsauce group of companies. A keen motorcyclist and rugby enthusiast, Andrew’s legal expertise keeps Stream flowing on track as the company grows and progresses.